検索結果
-
荏原の業績はこれから急拡大するよ。 ◆ Ebara Executive Miyaki: “Supporting the Decarbonization of the Petrochemical Industry Through Small Modular Reactors” The Nikkei – November 18, 2026, 5:00 a.m. (JST) Ebara Corporation (headquartered in Ota-ku, Tokyo) sees new business opportunities in small modular reactors (SMRs), a next-generation nuclear reactor technology. In collaboration with U.S.-based NuScale Power Corporation, Ebara is developing a steam compressor designed to enable SMRs to be used in petrochemical production. We spoke with Takanobu Miyaki, Executive Officer in charge of Ebara’s Energy Business, about the company’s strategy. NuScale Power Corporation is an emerging U.S. company headquartered in Oregon that specializes in the design of next-generation nuclear reactors known as small modular reactors (SMRs). For the fiscal year ended December 2025, the company reported revenue of $31.479 million (approximately ¥5.016 billion). It has 428 employees.
-
イランに攻撃できる大義名分を作るのは自作自演の911と同じ Exclusive: US intel indicates Iran developing plans to potentially a dirty bomb in Washington, sources say CNN politics
-
NHKワールド JAPANの医療情報番組「Medical Frontiers」への出演IR テー マは、Against the Clock: Developing a New Stroke Drug 時間との戦い 〜新たな脳梗塞治療薬の開発〜 とのことで、前の「ヴィランの言い分」よりもガチな内容になりそうです。 ティムスの蓮見会長のほか、東北大学の遠藤英徳教授、新妻邦泰教授、寳澤篤教授なども出演。 ただ、ストリーミングとかケーブルTVだけで、普通のTVでは見られないのかな?
-
さてどうなるかな。 TRL Drones is developing both small electric-powered drones and larger jet-powered drones. In a March 2026 Business Insider article, the company's representative stated that both types of drones are being used in Ukraine. TRL Drones itself also shared the article on its official LinkedIn account.
-
DEVELOPING: Iran’s official news agency IRNA says that locals on Qeshm Island, located in the Strait of Hormuz, reported that two projectiles “impacted in the Susa area” of the island.
-
MASH 米国から世界へ表現が変わってるね 8月 Gyre is developing F351 for two primary indications: CHB-associated liver fibrosis in the PRC and MASH-associated liver fibrosis initially in the United States. Gyreは、中国におけるCHB関連肝線維症と、米国におけるMASH関連肝線維症の2つの主要適応症のためにF351を開発しています。 11月 Gyre is developing F351 for two primary indications: CHB-associated liver fibrosis in the PRC and MASH-associated liver fibrosis for global markets Gyreは、中国におけるCHB関連肝線維症と、世界市場向けのMASH関連肝線維症という2つの主要適応症のためにF351を開発しています。
-
Linkedinより引用です Akatsuki Therapeutics Akatsuki Therapeutics will be attending BIO-Europe 2026, November 9–11, in Cologne, Germany. We are pleased to have been selected for JETRO’s support program. Junya Yamazaki, President, and Miguel Forte, Chair of the Board, will be joining the event to meet with investors, pharmaceutical companies, and potential strategic partners. Akatsuki is developing next-generation, multi-gene engineered, iPSC-derived NK (eNK) cell therapies for difficult-to-treat solid tumors. Our lead program, AKT-01, is being developed initially for malignant pleural mesothelioma, alongside a broader off-the-shelf eNK platform for additional solid tumors and combination strategies. We look forward to connecting with the global biotech community in Cologne and exploring opportunities for investment, partnering, and collaboration. If you would like to meet with us in Cologne, please get in touch. #BIOEurope
-
今日のサウジアラビア案件の契約先、韓国のNAVERの関連会社みたいですね。 韓国のマップもDMPは保持してるので、面白そう。 The newly established strategic JV, “NAVER Innovation,” will be the first business entity under “NAVER Arabia,” NAVER’s regional headquarters. It will be jointly funded by NAVER Cloud and NHC Innovation, NHC’s digital subsidiary. NAVER Innovation will focus on developing and operating a map-based super app that supports various aspects of daily life, such as housing and transportation, for Saudi citizens and visitors, with plans to expand upon the existing digital twin–based services.
Developing targ…
2026/11/18 15:41
Developing targeted drugs for boron neutron capture therapy to treat refractory cancers https://www.nature.com/articles/d43747-021-00008-y あのNature誌の査読クリアしての掲載、ななめにザッと読んだだけですが、なんか凄いこと3点あるようです。 特に、どこかで最近読んだ記憶のある「京大の革新的DDS」との関連なのか!?: Nanoparticles In collaboration with Kyoto University, TLS is also developing a novel class of nanoparticle carriers called BPMOs (biodegradable mesoporous organosilica nanoparticles) that can carry large 10B loads and deliver them with high selectivity to cancer cells. Nanoparticles of the size being made under this collaboration have been shown to home to tumor cells as a result of what is known as an EPR effect, enhanced penetration and retention.